Valuation: ImmuCell Corporation

Market Cap 9.07Cr 7.96Cr 7.49Cr 6.84Cr 13Cr 869.13Cr 13Cr 90Cr 35Cr 443.11Cr 34Cr 33Cr 1.44TCr P/E 2024
-19.5x
P/E 2025 -51.3x
Enterprise Value 10Cr 8.79Cr 8.26Cr 7.55Cr 14Cr 959.05Cr 14Cr 99Cr 38Cr 488.96Cr 38Cr 37Cr 1.59TCr EV / Sales 2024
2.16x
EV / Sales 2025 2.35x
Free-Float
67.82%
Yield 2024 *
-
Yield 2025 -
1 week+3.95%
Current month+2.04%
1 month-0.70%
3 months+1.27%
6 months+55.85%
Current year+62.44%
1 week 9.68
Extreme 9.68
10.16
1 month 9.46
Extreme 9.46
10.34
Current year 5.75
Extreme 5.75
12.1
1 year 4.52
Extreme 4.52
12.1
3 years 3.34
Extreme 3.34
12.1
5 years 3.34
Extreme 3.34
12.1
10 years 0
Extreme 0
13.2
Manager TitleAgeSince
Chief Executive Officer 54 01/11/2025
Director of Finance/CFO 47 07/04/2025
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Chairman 69 01/12/2013
Director/Board Member 61 31/03/2014
Director/Board Member 66 10/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
15/04/26 Free

Chairman

11,933 0.1319%
15/04/26 Free

Director

17,899 0.1979%
15/04/26 Free

Director

11,933 0.1319%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+3.95%+61.13%+84.32% 9.07Cr
-1.64%+1.16%+54.09%+109.07% 1,02600Cr
-0.01%+0.71%+52.44%+67.71% 65TCr
-0.05%+0.98%+19.08%+73.55% 47TCr
-0.30%+0.19%+39.25%+45.02% 35TCr
+0.94%+2.28%+21.29%+28.28% 27TCr
-0.52%-0.51%+10.29%+10.45% 26TCr
-1.01%+7.90%+41.59%+51.70% 22TCr
-0.85%+2.50%+32.32%+101.80% 19TCr
-1.23%-10.70%-32.86%-60.85% 17TCr
Average -0.14%+1.53%+29.86%+51.10% 35.99TCr
Weighted average by Cap. +0.18%+1.26%+36.20%+65.73%

Financials

2024 2025
Net sales 2.65Cr 2.33Cr 2.19Cr 2Cr 3.73Cr 253.78Cr 3.76Cr 26Cr 10Cr 129.39Cr 9.95Cr 9.73Cr 419.51Cr 2.76Cr 2.43Cr 2.28Cr 2.09Cr 3.9Cr 264.81Cr 3.93Cr 27Cr 11Cr 135.01Cr 10Cr 10Cr 437.73Cr
Net income -21.57L -18.93L -17.79L -16.27L -30.4L -21Cr -30.62L -2.14Cr -82.85L -11Cr -80.99L -79.21L -34Cr -10.4L -9L -9L -8L -14.66L -9.96Cr -14.77L -1.03Cr -39.96L -5.08Cr -39.06L -38.2L -16Cr
Net Debt 1.13Cr 99.54L 93.57L 85.55L 1.6Cr 108.64Cr 1.61Cr 11Cr 4.36Cr 55Cr 4.26Cr 4.17Cr 179.59Cr 93.88L 82.39L 77.45L 70.81L 1.32Cr 90Cr 1.33Cr 9.3Cr 3.61Cr 46Cr 3.53Cr 3.45Cr 148.65Cr
Logo ImmuCell Corporation
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
Employees
73
Date Price Change Volume
23/26/23 $9.990 0.00% 7,866
22/26/22 $9.990 -1.38% 36,073
21/26/21 $10.13 +1.81% 3,184
18/26/18 $9.950 -0.30% 10,036
17/26/17 $9.980 +3.85% 32,936
  1. Stock Market
  2. Stocks
  3. ICCC Stock